Remote photobiomodulation targeted at the abdomen or legs provides effective neuroprotection against parkinsonian MPTP insult

Abstract

AbstractPhotobiomodulation (PBM)—the irradiation of tissue with low‐intensity light—mitigates neuropathology in rodent models of Parkinson's disease (PD) when targeted at the head (‘transcranial PBM’). In humans, however, attenuation of light energy by the scalp and skull necessitates a different approach. We have reported that targeting PBM at the body also protects the brain by a mechanism that spreads from the irradiated tissue (‘remote PBM’), although the optimal peripheral tissue target for remote PBM is currently unclear. This study compared the neuroprotective efficacy of remote PBM targeting the abdomen or leg with transcranial PBM, in mouse and non‐human primate models of PD. In a pilot study, the neurotoxin MPTP was used to induce PD in non‐human primates; PBM (670 nm, 50 mW/cm2, 6 min/day) of the abdomen (n = 1) was associated with fewer clinical signs and more surviving midbrain dopaminergic cells relative to MPTP‐injected non‐human primates not treated with PBM. Validation studies in MPTP‐injected mice (n = 10 per group) revealed a significant rescue of midbrain dopaminergic cells in mice receiving PBM to the abdomen (~80%, p < .0001) or legs (~80%, p < .0001), with comparable rescue of axonal terminals in the striatum. Strikingly, this degree of neuroprotection was at least as, if not more, pronounced than that achieved with transcranial PBM. These findings confirm that remote PBM provides neuroprotection against MPTP‐induced destruction of the key circuitry underlying PD, with both the abdomen and legs serving as viable remote targets. This should provide the impetus for a comprehensive investigation of remote PBM‐induced neuroprotection in other models of PD and, ultimately, human patients.